Comparative Pharmacology
Head-to-head clinical analysis: VIMOVO versus ZORVOLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIMOVO versus ZORVOLEX.
VIMOVO vs ZORVOLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VIMOVO (esomeprazole and naproxen) is a fixed-dose combination. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, thereby reducing inflammation, pain, and fever. Esomeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase in gastric parietal cells. The combination is intended to reduce the risk of NSAID-associated gastric ulcers.
ZORVOLEX (diclofenac) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever.
One tablet (naproxen 500 mg/esomeprazole 20 mg) orally twice daily.
50 mg orally every 8 hours or 100 mg orally every 12 hours; maximum 200 mg/day.
None Documented
None Documented
Naproxen: 12-17 hours (prolonged in elderly and renal impairment; dosing interval typically 12 hours). Esomeprazole: 1-1.5 hours (metabolized by CYP2C19 and CYP3A4; no accumulation after repeated dosing).
Terminal elimination half-life of the dual-release formulation is approximately 6-7 hours. Clinical context: Allows twice-daily dosing for sustained analgesic effect.
Renal 50% as naproxen metabolites, <1% unchanged naproxen; less than 1% excreted unchanged in feces as esomeprazole; esomeprazole metabolites excreted in urine 80% and feces 20%.
Renal excretion of metabolites and conjugates accounts for approximately 50% of the dose, with biliary/fecal elimination of the remainder. Less than 5% is excreted unchanged in urine.
Category C
Category C
NSAID/PPI Combination
NSAID